This Article Full Text Full Text (PDF) All Versions of this Article: 37/11/2666    most recent 01.STR.0000244550.27843.41v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Oprisiu-Fournier, R. Articles by Fournier, A. Search for Related Content PubMed PubMed Citation Articles by Oprisiu-Fournier, R. Articles by Fournier, A.

(Stroke. 2006;37:2666.)
© 2006 American Heart Association, Inc.

Letters to the Editor

AT1 Receptor Blockers for Cognition Decline After Cardiac Surgery?

Geriatrics Department, University Hospital, Amiens, France

Jean-Michel Achard, MD, PhD

Physiology Department, University Hospital, Limoges, France

Franz H. Messerli, MD

Cardiology Department, St-Luke Roosevelt Hospital Center, New York, New York

Sandra E. Black, MD

Neurology Division Sunnybrook, Women’s College Health Science Center, University of Toronto, Canada

Albert Fournier, MD

Internal Medicine Nephrology Department, University Hospital, Amiens, France

An extract of the first 250 words of the full text is provided, because this article has no abstract.

To the Editor:

We read with interest the review article on stroke and encephalopathy after cardiac surgery¹ and the related editorial.² We agree that assessing these complications provides a unique clinical opportunity for evaluating preventive strategies because patients at higher risk can be identified before surgery. We would like to add to the list of potential cerebroprotective agents proposed (gangliosides, glutamate receptor antagonists, antioxidants) the angiotensin AT1 receptor blockers (AT1RB).

Both angiotensin receptor blockers and angiotensin-converting enzyme inhibitors are widely used in cardiac patients before surgery and are usually resumed after transient discontinuation. Although their cardiac protective effects have been proven globally comparable (VALIANT³) their cerebroprotective effect (regarding both stroke and cognitive dysfunction) may be quite different. Indeed, the relative risk of stroke with angiotensin-converting enzyme inhibitors therapy compared with dihydropyridine calcium antagonists has been estimated at 1.12 (93% CI, 1.01 to 1.25).⁴ In contrast, at comparable blood pressure reduction, stroke recurrence with the AT1RB eprosartan was significantly lower (0.75 [95%, 0.58; 0.97; P=0.03]) when compared with nitrendipine in the MOSES trial.^5,6

This superiority of the AT1RB over the dihydropyridine calcium antagonists in stroke prevention may be explained by the fact that AT1RBs, by blocking the angiotensin II–mediated suppression of renin secretion, are more powerful stimulators of renin secretion and therefore of angiotensin II formation than are calcium-antagonists. This has been confirmed in a crossover study in hypertensive patients.⁷ Long-acting dihydropyridines and short-acting nondihydropyridines may stimulate renin secretion only by activating the sympathetic nervous system with variable intensity.^8,9

. . . [Full Text of this Article]